The Biopharm Brief: Microbiome Fast Track, Leo Pharma Gene Therapy Deal, AAV Automation Advances

May 01, 09:03 PM
Headliner
Share
Subscribe

Microbiome therapies gain FDA Fast Track status, Leo Pharma expands into gene therapy via acquisition, and automation improves AAV manufacturing efficiency.

Share
Subscribe
Next
The BioPharm Brief: Breakthroughs, Buyouts, and Biologics
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief
The BioPharm Brief: Regulatory Shifts, Rare Disease Innovation, and Precision Drug Development Trends
by The BioPharm Brief